Chimerix, Inc. Stock Börse Stuttgart

Chimerix, Inc. is a biopharmaceutical company. The Company’s advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. It is conducting phase I dose escalation studies of ONC206 to evaluate safety and PK data. The second-generation imipridone (ONC206) is in dose-escalating clinical trials for adult and pediatric patients with primary central nervous system tumors. Its other product candidates include ONC212 and CMX521. ONC212 is an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. CMX521 is a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. CMX521 is not mutagenic, clastogenic, or associated with mitochondrial toxicity. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides. This library includes approximately 3,500 nucleoside analog compounds. It is a wholly owned subsidiary of Jazz Pharmaceuticals plc.